Skip to main content
Top
Published in: International Journal of Pediatric Endocrinology 1/2014

Open Access 01-12-2014 | Review

Pediatric Graves’ disease: management in the post-propylthiouracil Era

Author: Scott A Rivkees

Published in: International Journal of Pediatric Endocrinology | Issue 1/2014

Login to get access

Abstract

The most prevalent cause of thyrotoxicosis in children is Graves’ disease (GD), and remission occurs only in a modest proportion of patients. Thus most pediatric patients with GD will need treatment with radioactive iodine (RAI; 131I) or surgical thyroidectomy. When antithyroid drugs (ATDs) are prescribed, only methimazole (MMI) should be administered, as PTU is associated with an unacceptable risk of severe liver injury. If remission does not occur following ATD therapy, 131I or surgery should be contemplated. When 131I is administered, dosages should be greater than 150 uCi/gm of thyroid tissue, with higher dosages needed for large glands. Considering that there will be low-level whole body radiation exposure associated with 131I, this treatment should be avoided in young children. When surgery is performed near total or total-thyroidectomy is the recommended procedure. Complications for thyroidectomy in children are considerably higher than in adults, thus an experienced thyroid surgeon is needed when children are operated on. Most importantly, the care of children with GD can be complicated and requires physicians with expertise in the area.
Literature
1.
go back to reference Abraham-Nordling M, Torring O, Lantz M, Hallengren B, Ohrling H, Lundell G, Calissendorff J, Jörneskog G, Wallin G: Incidence of hyperthyroidism in Stockholm, Sweden, 2003–2005. Eur J Endocrinol/Eur Fed Endocr Soc. 2008, 158: 823-827.CrossRef Abraham-Nordling M, Torring O, Lantz M, Hallengren B, Ohrling H, Lundell G, Calissendorff J, Jörneskog G, Wallin G: Incidence of hyperthyroidism in Stockholm, Sweden, 2003–2005. Eur J Endocrinol/Eur Fed Endocr Soc. 2008, 158: 823-827.CrossRef
3.
go back to reference Smith J, Brown RS: Persistence of thyrotropin (TSH) receptor antibodies in children and adolescents with Graves' disease treated using antithyroid medication. Thyroid. 2007, 17: 1103-1107.PubMedCrossRef Smith J, Brown RS: Persistence of thyrotropin (TSH) receptor antibodies in children and adolescents with Graves' disease treated using antithyroid medication. Thyroid. 2007, 17: 1103-1107.PubMedCrossRef
4.
go back to reference Rivkees SA, Sklar C, Freemark M: Clinical review 99: The management of Graves' disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metabol. 1998, 83: 3767-3776. Rivkees SA, Sklar C, Freemark M: Clinical review 99: The management of Graves' disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metabol. 1998, 83: 3767-3776.
6.
go back to reference Chapman EM: History of the discovery and early use of radioactive iodine. JAMA. 1983, 250: 2042-2044.PubMedCrossRef Chapman EM: History of the discovery and early use of radioactive iodine. JAMA. 1983, 250: 2042-2044.PubMedCrossRef
8.
go back to reference Talbot NB SE, McArthur JW, Crawford JD: Functional Endocrinology: from Birth to Adolescence. 1952, Cambridge: Harvard University Press, 1-51. Talbot NB SE, McArthur JW, Crawford JD: Functional Endocrinology: from Birth to Adolescence. 1952, Cambridge: Harvard University Press, 1-51.
9.
go back to reference Cooper DS: Antithyroid drugs for the treatment of hyperthyroidism caused by Graves' disease. Endocrinol Metab Clin North Am. 1998, 27: 225-247.PubMedCrossRef Cooper DS: Antithyroid drugs for the treatment of hyperthyroidism caused by Graves' disease. Endocrinol Metab Clin North Am. 1998, 27: 225-247.PubMedCrossRef
10.
go back to reference Rivkees SA: 63 Years and 715 Days to the “Boxed Warning”: Unmasking of the Propylthiouracil Problem. Int J Pediatr Endocrinol. 2010, 2010: Article ID 658267, 3 pages, 2010. doi:10.1155/2010/658267 Rivkees SA: 63 Years and 715 Days to the “Boxed Warning”: Unmasking of the Propylthiouracil Problem. Int J Pediatr Endocrinol. 2010, 2010: Article ID 658267, 3 pages, 2010. doi:10.1155/2010/658267
11.
go back to reference Rivkees SA, Mattison DR: Ending propylthiouracil-induced liver failure in children. N Engl J Med. 2009, 360: 1574-1575.PubMedCrossRef Rivkees SA, Mattison DR: Ending propylthiouracil-induced liver failure in children. N Engl J Med. 2009, 360: 1574-1575.PubMedCrossRef
12.
go back to reference Rivkees SA, Mattison DR: Propylthiouracil (PTU) Hepatoxicity in Children and Recommendations for Discontinuation of Use. Int J Pediatr Endocrinol. 2009, 2009: 132041-PubMedCentralPubMedCrossRef Rivkees SA, Mattison DR: Propylthiouracil (PTU) Hepatoxicity in Children and Recommendations for Discontinuation of Use. Int J Pediatr Endocrinol. 2009, 2009: 132041-PubMedCentralPubMedCrossRef
13.
go back to reference Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P: Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 2004, 10: 1018-1023.PubMedCrossRef Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P: Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 2004, 10: 1018-1023.PubMedCrossRef
14.
go back to reference Nakamura H, Noh JY, Itoh K, Fukata S, Miyauchi A, Hamada N: Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab. 2007, 92: 2157-2162.PubMedCrossRef Nakamura H, Noh JY, Itoh K, Fukata S, Miyauchi A, Hamada N: Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab. 2007, 92: 2157-2162.PubMedCrossRef
15.
go back to reference Nicholas WC, Fischer RG, Stevenson RA, Bass JD: Single daily dose of methimazole compared to every 8 hours propylthiouracil in the treatment of hyperthyroidism. South Med J. 1995, 88: 973-976.PubMedCrossRef Nicholas WC, Fischer RG, Stevenson RA, Bass JD: Single daily dose of methimazole compared to every 8 hours propylthiouracil in the treatment of hyperthyroidism. South Med J. 1995, 88: 973-976.PubMedCrossRef
16.
go back to reference Sato H, Harada S, Yokoya S, Tanaka T, Asayama K, Mori M, Sasaki N: Treatment for childhood-onset Graves' disease in Japan: results of a nationwide questionnaire survey of pediatric endocrinologists and thyroidologists. Thyroid. 2007, 17: 67-72.PubMedCrossRef Sato H, Harada S, Yokoya S, Tanaka T, Asayama K, Mori M, Sasaki N: Treatment for childhood-onset Graves' disease in Japan: results of a nationwide questionnaire survey of pediatric endocrinologists and thyroidologists. Thyroid. 2007, 17: 67-72.PubMedCrossRef
17.
go back to reference Cassio A, Corrias A, Gualandi S, Tato' L, Cesaretti G, Volta C, Weber G, Bona G, Cappa M, Bal M, Bellone J, Cicognani A: Influence of gender and pubertal stage at diagnosis on growth outcome in childhood thyrotoxicosis: results of a collaborative study. Clin Endocrinol (Oxf). 2006, 64: 53-57.CrossRef Cassio A, Corrias A, Gualandi S, Tato' L, Cesaretti G, Volta C, Weber G, Bona G, Cappa M, Bal M, Bellone J, Cicognani A: Influence of gender and pubertal stage at diagnosis on growth outcome in childhood thyrotoxicosis: results of a collaborative study. Clin Endocrinol (Oxf). 2006, 64: 53-57.CrossRef
18.
go back to reference Dotsch J, Rascher W, Dorr HG: Graves disease in childhood: a review of the options for diagnosis and treatment. Paediatr Drugs. 2003, 5: 95-102.PubMedCrossRef Dotsch J, Rascher W, Dorr HG: Graves disease in childhood: a review of the options for diagnosis and treatment. Paediatr Drugs. 2003, 5: 95-102.PubMedCrossRef
19.
go back to reference Dotsch J, Siebler T, Hauffa BP, Doeker B, Andler W, Bettendorf M, Heinrich U, Gohlke B, Albers N, Willgerodt H, Kiess W: Diagnosis and management of juvenile hyperthyroidism in Germany: a retrospective multicenter study. J Pediatric Endocrinol. 2000, 13: 879-885.CrossRef Dotsch J, Siebler T, Hauffa BP, Doeker B, Andler W, Bettendorf M, Heinrich U, Gohlke B, Albers N, Willgerodt H, Kiess W: Diagnosis and management of juvenile hyperthyroidism in Germany: a retrospective multicenter study. J Pediatric Endocrinol. 2000, 13: 879-885.CrossRef
20.
go back to reference Slyper AH, Wyatt D, Boudreau C: Effective methimazole dose for childhood Grave's disease and use of free triiodothyronine combined with concurrent thyroid-stimulating hormone level to identify mild hyperthyroidism and delayed pituitary recovery. J Pediatr Endocrinol Metab. 2005, 18: 597-602.PubMedCrossRef Slyper AH, Wyatt D, Boudreau C: Effective methimazole dose for childhood Grave's disease and use of free triiodothyronine combined with concurrent thyroid-stimulating hormone level to identify mild hyperthyroidism and delayed pituitary recovery. J Pediatr Endocrinol Metab. 2005, 18: 597-602.PubMedCrossRef
21.
go back to reference Abraham P, Avenell A, Watson WA, Park CM, Bevan JS: Antithyroid drug regimen for treating Graves' hyperthyroidism. Cochrane Database Syst Rev. 2005, 2: CD003420-PubMed Abraham P, Avenell A, Watson WA, Park CM, Bevan JS: Antithyroid drug regimen for treating Graves' hyperthyroidism. Cochrane Database Syst Rev. 2005, 2: CD003420-PubMed
22.
go back to reference Razvi S, Vaidya B, Perros P, Pearce SH: What is the evidence behind the evidence-base? The premature death of block-replace antithyroid drug regimens for Graves' disease. Eur J Endocrinol/Eur Fed Endocr Soc. 2006, 154: 783-786.CrossRef Razvi S, Vaidya B, Perros P, Pearce SH: What is the evidence behind the evidence-base? The premature death of block-replace antithyroid drug regimens for Graves' disease. Eur J Endocrinol/Eur Fed Endocr Soc. 2006, 154: 783-786.CrossRef
23.
go back to reference Cooper DS, Goldminz D, Levin AA, Ladenson PW, Daniels GH, Molitch ME, Ridgway EC: Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose. Ann Intern Med. 1983, 98: 26-29.PubMedCrossRef Cooper DS, Goldminz D, Levin AA, Ladenson PW, Daniels GH, Molitch ME, Ridgway EC: Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose. Ann Intern Med. 1983, 98: 26-29.PubMedCrossRef
25.
go back to reference Rivkees SA, Stephenson K, Dinauer C: Adverse events associated with methimazole therapy of graves' disease in children. Int J Pediatr Endocrinol. 2010, 2010: 176970-PubMedCentralPubMedCrossRef Rivkees SA, Stephenson K, Dinauer C: Adverse events associated with methimazole therapy of graves' disease in children. Int J Pediatr Endocrinol. 2010, 2010: 176970-PubMedCentralPubMedCrossRef
26.
go back to reference Tajiri J, Noguchi S: Antithyroid drug-induced agranulocytosis: how has granulocyte colony-stimulating factor changed therapy?. Thyroid. 2005, 15: 292-297.PubMedCrossRef Tajiri J, Noguchi S: Antithyroid drug-induced agranulocytosis: how has granulocyte colony-stimulating factor changed therapy?. Thyroid. 2005, 15: 292-297.PubMedCrossRef
27.
go back to reference Harper L, Chin L, Daykin J, Allahabadia A, Heward J, Gough SC, Savage CO, Franklyn JA: Propylthiouracil and carbimazole associated-antineutrophil cytoplasmic antibodies (ANCA) in patients with Graves' disease. Clin Endocrinol (Oxf). 2004, 60: 671-675.CrossRef Harper L, Chin L, Daykin J, Allahabadia A, Heward J, Gough SC, Savage CO, Franklyn JA: Propylthiouracil and carbimazole associated-antineutrophil cytoplasmic antibodies (ANCA) in patients with Graves' disease. Clin Endocrinol (Oxf). 2004, 60: 671-675.CrossRef
29.
30.
go back to reference Poomthavorn P, Mahachoklertwattana P, Tapaneya-Olarn W, Chuansumrit A, Chunharas A: Antineutrophilic cytoplasmic antibody-positive systemic vasculitis associated with propylthiouracil therapy: report of 2 children with Graves' disease. J Med Assoc Thai. 2002, 85 (Suppl 4): S1295-S1301.PubMed Poomthavorn P, Mahachoklertwattana P, Tapaneya-Olarn W, Chuansumrit A, Chunharas A: Antineutrophilic cytoplasmic antibody-positive systemic vasculitis associated with propylthiouracil therapy: report of 2 children with Graves' disease. J Med Assoc Thai. 2002, 85 (Suppl 4): S1295-S1301.PubMed
31.
go back to reference Fujieda M, Suzuki K, Sato H, Hattori M, Wada N, Tsuchiya M, Okamoto N, Murata T, Matsudaira M, Shimizu M, Ohta K, Naruse K, Sugihara S, Wakiguchi H: Epitope analysis of myeloperoxidase-specific antineutrophil cytoplasmic autoantibodies (MPO-ANCA) in childhood onset Graves' disease treated with propylthiouracil. Clin Nephrol. 2005, 63: 437-445.PubMedCrossRef Fujieda M, Suzuki K, Sato H, Hattori M, Wada N, Tsuchiya M, Okamoto N, Murata T, Matsudaira M, Shimizu M, Ohta K, Naruse K, Sugihara S, Wakiguchi H: Epitope analysis of myeloperoxidase-specific antineutrophil cytoplasmic autoantibodies (MPO-ANCA) in childhood onset Graves' disease treated with propylthiouracil. Clin Nephrol. 2005, 63: 437-445.PubMedCrossRef
33.
go back to reference Hamburger JI: Management of hyperthyroidism in children and adolescents. J Clin Endocrinol Metab. 1985, 60: 1019-1024.PubMedCrossRef Hamburger JI: Management of hyperthyroidism in children and adolescents. J Clin Endocrinol Metab. 1985, 60: 1019-1024.PubMedCrossRef
34.
go back to reference Glaser NS, Styne DM: Predictors of early remission of hyperthyroidism in children. J Clin Endocrinol Metab. 1997, 82: 1719-1726.PubMed Glaser NS, Styne DM: Predictors of early remission of hyperthyroidism in children. J Clin Endocrinol Metab. 1997, 82: 1719-1726.PubMed
35.
go back to reference Glaser NS, Styne DM: Predicting the likelihood of remission in children with Graves' disease: a prospective, multicenter study. Pediatrics. 2008, 121: e481-e488.PubMedCrossRef Glaser NS, Styne DM: Predicting the likelihood of remission in children with Graves' disease: a prospective, multicenter study. Pediatrics. 2008, 121: e481-e488.PubMedCrossRef
36.
go back to reference Kaguelidou F, Alberti C, Castanet M, Guitteny MA, Czernichow P, Leger J: Predictors of Autoimmune Hyperthyroidism Relapse in Children after Discontinuation of Antithyroid Drug Treatment. J Clin Endocrinol Metab. 2008, 10: 3817-3826.CrossRef Kaguelidou F, Alberti C, Castanet M, Guitteny MA, Czernichow P, Leger J: Predictors of Autoimmune Hyperthyroidism Relapse in Children after Discontinuation of Antithyroid Drug Treatment. J Clin Endocrinol Metab. 2008, 10: 3817-3826.CrossRef
37.
go back to reference Leger J, Gelwane G, Kaguelidou F, Benmerad M, Alberti C: Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves' disease: national long-term cohort study. J Clin Endocrinol Metab. 2012, 97: 110-119.PubMedCrossRef Leger J, Gelwane G, Kaguelidou F, Benmerad M, Alberti C: Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves' disease: national long-term cohort study. J Clin Endocrinol Metab. 2012, 97: 110-119.PubMedCrossRef
38.
go back to reference Weetman AP: Graves' hyperthyroidism: how long should antithyroid drug therapy be continued to achieve remission?. Nat Clin Pract Endocrinol Metab. 2006, 2: 2-3.PubMedCrossRef Weetman AP: Graves' hyperthyroidism: how long should antithyroid drug therapy be continued to achieve remission?. Nat Clin Pract Endocrinol Metab. 2006, 2: 2-3.PubMedCrossRef
39.
go back to reference Allannic H, Fauchet R, Orgiazzi J, Madec AM, Genetet B, Lorcy Y, Le Guerrier AM, Delambre C, Derennes V: Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab. 1990, 70: 675-679.PubMedCrossRef Allannic H, Fauchet R, Orgiazzi J, Madec AM, Genetet B, Lorcy Y, Le Guerrier AM, Delambre C, Derennes V: Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab. 1990, 70: 675-679.PubMedCrossRef
40.
go back to reference Garcia-Mayor RV, Paramo C, Luna Cano R, Perez Mendez LF, Galofre JC, Andrade A: Antithyroid drug and Graves' hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission. J Endocrinol Invest. 1992, 15: 815-820.PubMedCrossRef Garcia-Mayor RV, Paramo C, Luna Cano R, Perez Mendez LF, Galofre JC, Andrade A: Antithyroid drug and Graves' hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission. J Endocrinol Invest. 1992, 15: 815-820.PubMedCrossRef
41.
go back to reference Maugendre D, Gatel A, Campion L, Massart C, Guilhem I, Lorcy Y, Lescouarch J, Herry JY, Allannic H: Antithyroid drugs and Graves' disease–prospective randomized assessment of long-term treatment. Clin Endocrinol (Oxf). 1999, 50: 127-132.CrossRef Maugendre D, Gatel A, Campion L, Massart C, Guilhem I, Lorcy Y, Lescouarch J, Herry JY, Allannic H: Antithyroid drugs and Graves' disease–prospective randomized assessment of long-term treatment. Clin Endocrinol (Oxf). 1999, 50: 127-132.CrossRef
42.
go back to reference Shulman DI, Muhar I, Jorgensen EV, Diamond FB, Bercu BB, Root AW: Autoimmune hyperthyroidism in prepubertal children and adolescents: comparison of clinical and biochemical features at diagnosis and responses to medical therapy. Thyroid. 1997, 7: 755-760.PubMedCrossRef Shulman DI, Muhar I, Jorgensen EV, Diamond FB, Bercu BB, Root AW: Autoimmune hyperthyroidism in prepubertal children and adolescents: comparison of clinical and biochemical features at diagnosis and responses to medical therapy. Thyroid. 1997, 7: 755-760.PubMedCrossRef
43.
go back to reference Ma C, Kuang A, Xie J, Liu G: Radioiodine treatment for pediatric Graves' disease. Cochrane Database Syst Rev. 2008, 3: CD006294-PubMed Ma C, Kuang A, Xie J, Liu G: Radioiodine treatment for pediatric Graves' disease. Cochrane Database Syst Rev. 2008, 3: CD006294-PubMed
44.
go back to reference Lippe BM, Landaw EM, Kaplan SA: Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years. J Clin Endocrinol Metab. 1987, 64: 1241-1245.PubMedCrossRef Lippe BM, Landaw EM, Kaplan SA: Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years. J Clin Endocrinol Metab. 1987, 64: 1241-1245.PubMedCrossRef
45.
go back to reference Gruneiro-Papendieck L, Chiesa A, Finkielstain G, Heinrich JJ: Pediatric Graves' disease: outcome and treatment. J Pediatr Endocrinol Metab. 2003, 16: 1249-1255.PubMed Gruneiro-Papendieck L, Chiesa A, Finkielstain G, Heinrich JJ: Pediatric Graves' disease: outcome and treatment. J Pediatr Endocrinol Metab. 2003, 16: 1249-1255.PubMed
46.
go back to reference Lazar L, Kalter-Leibovici O, Pertzelan A, Weintrob N, Josefsberg Z, Phillip M: Thyrotoxicosis in prepubertal children compared with pubertal and postpubertal patients. J Clin Endocrinol Metab. 2000, 85: 3678-3682.PubMedCrossRef Lazar L, Kalter-Leibovici O, Pertzelan A, Weintrob N, Josefsberg Z, Phillip M: Thyrotoxicosis in prepubertal children compared with pubertal and postpubertal patients. J Clin Endocrinol Metab. 2000, 85: 3678-3682.PubMedCrossRef
47.
go back to reference Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, Rocchi R, Martino E, Pinchera A: Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid. 1997, 7: 69-375.CrossRef Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, Rocchi R, Martino E, Pinchera A: Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid. 1997, 7: 69-375.CrossRef
48.
go back to reference Bouma DJ, Kammer H, Greer MA: Follow-up comparison of short-term versus 1-year antithyroid drug therapy for the thyrotoxicosis of Graves' disease. J Clin Endocrinol Metab. 1982, 55: 1138-1142.PubMedCrossRef Bouma DJ, Kammer H, Greer MA: Follow-up comparison of short-term versus 1-year antithyroid drug therapy for the thyrotoxicosis of Graves' disease. J Clin Endocrinol Metab. 1982, 55: 1138-1142.PubMedCrossRef
49.
go back to reference Greer MA, Kammer H, Bouma DJ: Short-term antithyroid drug therapy for the thyrotoxicosis of Graves' disease. N Engl J Med. 1977, 297: 173-176.PubMedCrossRef Greer MA, Kammer H, Bouma DJ: Short-term antithyroid drug therapy for the thyrotoxicosis of Graves' disease. N Engl J Med. 1977, 297: 173-176.PubMedCrossRef
50.
go back to reference Bing RF: Early remission in thyrotoxicosis produced by short coursed of treatment. Acta Endocrinol Suppl. 1982, 100: 221-223. Bing RF: Early remission in thyrotoxicosis produced by short coursed of treatment. Acta Endocrinol Suppl. 1982, 100: 221-223.
51.
go back to reference Salpeter SR, Ormiston TM, Salpeter EE: Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med. 2002, 137: 715-725.PubMedCrossRef Salpeter SR, Ormiston TM, Salpeter EE: Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med. 2002, 137: 715-725.PubMedCrossRef
52.
go back to reference Wintergerst KA, Rogers ES, Foster MB: Hyperthyroidism presenting with hyperglycemia in an adolescent female. J Pediatr Endocrinol Metab. 2011, 24: 385-387.PubMedCrossRef Wintergerst KA, Rogers ES, Foster MB: Hyperthyroidism presenting with hyperglycemia in an adolescent female. J Pediatr Endocrinol Metab. 2011, 24: 385-387.PubMedCrossRef
53.
go back to reference Gomez Cruz MJ, Jabbar M, Saini N, Eng D, Crawford B, Vazquez DM, Menon R, Chen M: Severe hypoglycemia secondary to methimazole-induced insulin autoimmune syndrome in a 16 year old African-American male. Pediatr Diabetes. 2012, 13: 652-655.PubMedCrossRef Gomez Cruz MJ, Jabbar M, Saini N, Eng D, Crawford B, Vazquez DM, Menon R, Chen M: Severe hypoglycemia secondary to methimazole-induced insulin autoimmune syndrome in a 16 year old African-American male. Pediatr Diabetes. 2012, 13: 652-655.PubMedCrossRef
54.
go back to reference Benavides VC, Rivkees SA: Myopathy associated with acute hypothyroidism following radioiodine therapy for graves disease in an adolescent. Int J Pediatr Endocrinol. 2010, 2010: doi:10.1155/2010/717303. Epub 2010 Sep 14 Benavides VC, Rivkees SA: Myopathy associated with acute hypothyroidism following radioiodine therapy for graves disease in an adolescent. Int J Pediatr Endocrinol. 2010, 2010: doi:10.1155/2010/717303. Epub 2010 Sep 14
55.
go back to reference van Veenendaal NR, Rivkees SA: Treatment of pediatric Graves' disease is associated with excessive weight gain. J Clin Endocrinol Metab. 2011, 96: 3257-3263.PubMedCentralPubMedCrossRef van Veenendaal NR, Rivkees SA: Treatment of pediatric Graves' disease is associated with excessive weight gain. J Clin Endocrinol Metab. 2011, 96: 3257-3263.PubMedCentralPubMedCrossRef
56.
go back to reference Williams ED: Biological effects of radiation on the thyroid. The Thyroid. Edited by: Braverman LE, Utiger RD. 1986, Phildelphia: J.B. Lippincott Co, 421-436. Williams ED: Biological effects of radiation on the thyroid. The Thyroid. Edited by: Braverman LE, Utiger RD. 1986, Phildelphia: J.B. Lippincott Co, 421-436.
57.
go back to reference Hertz BE, Schuller KE: Saul Hertz, Md (1905–1950): A Pioneer in the Use of Radioactive Iodine. Endocr Pract. 2010, 16: 713-715.PubMedCrossRef Hertz BE, Schuller KE: Saul Hertz, Md (1905–1950): A Pioneer in the Use of Radioactive Iodine. Endocr Pract. 2010, 16: 713-715.PubMedCrossRef
58.
go back to reference Sheline GE, McCormack KR, Galante M: Thyroid nodules occurring late after treatment of thryotoxicosis with radioiodine. J Clin Endocrinol Metab. 1962, 22: 8-17.PubMedCrossRef Sheline GE, McCormack KR, Galante M: Thyroid nodules occurring late after treatment of thryotoxicosis with radioiodine. J Clin Endocrinol Metab. 1962, 22: 8-17.PubMedCrossRef
59.
go back to reference Dobyns BM, Sheline GE, Workman JB, Tompkins EA, McConahey WM, Becker DV: Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the Cooperative Thyrotoxicosis Therapy Follow-up Study. J Clin Endocrinol Metab. 1974, 38: 976-998.PubMedCrossRef Dobyns BM, Sheline GE, Workman JB, Tompkins EA, McConahey WM, Becker DV: Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the Cooperative Thyrotoxicosis Therapy Follow-up Study. J Clin Endocrinol Metab. 1974, 38: 976-998.PubMedCrossRef
60.
go back to reference Goolden AWG, Davey JB: The ablation of normal thyroid tissue with iodine-131. Br J Radiol. 1963, 36: 340-345.PubMedCrossRef Goolden AWG, Davey JB: The ablation of normal thyroid tissue with iodine-131. Br J Radiol. 1963, 36: 340-345.PubMedCrossRef
61.
go back to reference Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI, Saenger EL: Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med. 1983, 309: 937-941.PubMedCrossRef Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI, Saenger EL: Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med. 1983, 309: 937-941.PubMedCrossRef
62.
go back to reference Levy WM, Schumacher OP, Gupta M: Treatment of childhood Graves' disease. A review with emphasis on radioiodine treatment. Cleveland Clin J Med. 1988, 55: 373-382.CrossRef Levy WM, Schumacher OP, Gupta M: Treatment of childhood Graves' disease. A review with emphasis on radioiodine treatment. Cleveland Clin J Med. 1988, 55: 373-382.CrossRef
63.
go back to reference Peters H, Fischer C, Bogner U, Reiners C, Schleusener H: Treatment of Graves' hyperthyroidism with radioiodine: results of a prospective randomized study. Thyroid. 1997, 7: 247-251.PubMedCrossRef Peters H, Fischer C, Bogner U, Reiners C, Schleusener H: Treatment of Graves' hyperthyroidism with radioiodine: results of a prospective randomized study. Thyroid. 1997, 7: 247-251.PubMedCrossRef
64.
go back to reference Graham GD, Burman KD: Radioiodine treatment of Graves' disease. An assessment of its potential risks. Ann Intern Med. 1986, 105: 900-905.PubMedCrossRef Graham GD, Burman KD: Radioiodine treatment of Graves' disease. An assessment of its potential risks. Ann Intern Med. 1986, 105: 900-905.PubMedCrossRef
65.
go back to reference Peters H, Fischer C, Bogner U, Reiners C, Schleusener H: Radioiodine therapy of Graves' hyperthyroidism: standard vs. calculated 131 iodine activity. Results from a prospective, randomized, multicentre study. Eur J Clin Invest. 1995, 25: 186-193.PubMedCrossRef Peters H, Fischer C, Bogner U, Reiners C, Schleusener H: Radioiodine therapy of Graves' hyperthyroidism: standard vs. calculated 131 iodine activity. Results from a prospective, randomized, multicentre study. Eur J Clin Invest. 1995, 25: 186-193.PubMedCrossRef
66.
go back to reference Becker DV, Hurly JR: Complications of radioiodine treatment of hyperthyroidism. Semin Nucl Med. 1971, 1: 442-460.PubMedCrossRef Becker DV, Hurly JR: Complications of radioiodine treatment of hyperthyroidism. Semin Nucl Med. 1971, 1: 442-460.PubMedCrossRef
67.
go back to reference Kadmon PM, Noto RB, Boney CM, Goodwin G, Gruppuso PA: Thyroid storm in a child following radioactive iodine (RAI) therapy: a consequence of RAI versus withdrawal of antithyroid medication. J Clin Endocrinol Metab. 2001, 86: 1865-1867.PubMedCrossRef Kadmon PM, Noto RB, Boney CM, Goodwin G, Gruppuso PA: Thyroid storm in a child following radioactive iodine (RAI) therapy: a consequence of RAI versus withdrawal of antithyroid medication. J Clin Endocrinol Metab. 2001, 86: 1865-1867.PubMedCrossRef
68.
go back to reference Refetoff S, Demeester-Mirkine N, Ermans AM, De Groot LJ: Rapid control of thyrotoxicosis with combined 131I, anthithyroid drugs and KI therapy. J Nucl Med Allied Sci. 1977, 21: 23-29.PubMed Refetoff S, Demeester-Mirkine N, Ermans AM, De Groot LJ: Rapid control of thyrotoxicosis with combined 131I, anthithyroid drugs and KI therapy. J Nucl Med Allied Sci. 1977, 21: 23-29.PubMed
69.
go back to reference Ross DS, Daniels GH, De Stefano P, Maloof F, Ridgway EC: Use of adjunctive potassium iodide after radioactive iodine (131I) treatment of Graves' hyperthyroidism. J Clin Endocrinol Metab. 1983, 57: 250-253.PubMedCrossRef Ross DS, Daniels GH, De Stefano P, Maloof F, Ridgway EC: Use of adjunctive potassium iodide after radioactive iodine (131I) treatment of Graves' hyperthyroidism. J Clin Endocrinol Metab. 1983, 57: 250-253.PubMedCrossRef
70.
go back to reference Rappaport B, Caplan R, De Groot LJ: Low-dose sodium iodine I 131 therapy in Graves disease. JAMA. 1973, 224: 1610-1613.CrossRef Rappaport B, Caplan R, De Groot LJ: Low-dose sodium iodine I 131 therapy in Graves disease. JAMA. 1973, 224: 1610-1613.CrossRef
71.
go back to reference Sridama V, DeGroot LJ: Treatment of Graves' disease and the course of opthalmopathy. Am J of Med. 1989, 87: 70-73.CrossRef Sridama V, DeGroot LJ: Treatment of Graves' disease and the course of opthalmopathy. Am J of Med. 1989, 87: 70-73.CrossRef
72.
go back to reference Goolden AW, Stewart JS: Long-term results from graded low dose radioactive iodine therapy for thyrotoxicosis. Clin Endocrinol (Oxf). 1986, 24: 217-222.CrossRef Goolden AW, Stewart JS: Long-term results from graded low dose radioactive iodine therapy for thyrotoxicosis. Clin Endocrinol (Oxf). 1986, 24: 217-222.CrossRef
73.
go back to reference McCullagh EP, Jelden GL, Rodriguez-Antunez A: Incidence of hypothyroidism following small doses of 131I in the treatment of Graves' disease. Oh State Med J. 1976, 72: 538-540. McCullagh EP, Jelden GL, Rodriguez-Antunez A: Incidence of hypothyroidism following small doses of 131I in the treatment of Graves' disease. Oh State Med J. 1976, 72: 538-540.
74.
go back to reference Dobyns BM: Radiation effects on the thyroid. Effects vary with dosage and sensitivity of the gland to radiation. RI Med J. 1975, 58 (94–7): 122-125. Dobyns BM: Radiation effects on the thyroid. Effects vary with dosage and sensitivity of the gland to radiation. RI Med J. 1975, 58 (94–7): 122-125.
75.
go back to reference Safa AM: Treatment of hyperthyroidism with a large initial dose of sodium iodine I 131. Arch Intern Med. 1975, 135: 673-675.PubMedCrossRef Safa AM: Treatment of hyperthyroidism with a large initial dose of sodium iodine I 131. Arch Intern Med. 1975, 135: 673-675.PubMedCrossRef
76.
go back to reference Chiovato L, Fiore E, Vitti P, Rocchi R, Rago T, Dokic D, Latrofa F, Mammoli C, Lippi F, Ceccarelli C, Pinchera A: Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab. 1998, 83: 40-46.PubMed Chiovato L, Fiore E, Vitti P, Rocchi R, Rago T, Dokic D, Latrofa F, Mammoli C, Lippi F, Ceccarelli C, Pinchera A: Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab. 1998, 83: 40-46.PubMed
77.
go back to reference Murakami Y, Takamatsu J, Sakane S, Kuma K, Ohsawa N: Changes in thyroid volumes in response to radioactive iodine for Graves' hyperthyroidism correlated with activity of throid-stimulatinf antibody and treatment outcome. J Clin Endocrinol Metab. 1996, 81: 3257-3260.PubMed Murakami Y, Takamatsu J, Sakane S, Kuma K, Ohsawa N: Changes in thyroid volumes in response to radioactive iodine for Graves' hyperthyroidism correlated with activity of throid-stimulatinf antibody and treatment outcome. J Clin Endocrinol Metab. 1996, 81: 3257-3260.PubMed
78.
go back to reference Hancock LD, Tuttle RM, LeMar H, Baumen J, Patience T: The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease. Clin Endocrinol (Oxf). 1997, 47: 425-430.CrossRef Hancock LD, Tuttle RM, LeMar H, Baumen J, Patience T: The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease. Clin Endocrinol (Oxf). 1997, 47: 425-430.CrossRef
79.
go back to reference Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA: Radioiodine treatment of hyperthyroidism-prognostic factors for outcome. J Clin Endocrinol Metab. 2001, 86: 3611-3617.PubMed Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA: Radioiodine treatment of hyperthyroidism-prognostic factors for outcome. J Clin Endocrinol Metab. 2001, 86: 3611-3617.PubMed
80.
81.
go back to reference Vitti P, Martino E, Aghini-Lombardi F, Rago T, Antonangeli L, Maccherini D, Nanni P, Loviselli A, Balestrieri A, Araneo G: Thyroid volume measurement by ultrasound in children as a tool for the assessment of mild iodine deficiency. J Clin Endocrinol Metab. 1994, 79: 600-603.PubMed Vitti P, Martino E, Aghini-Lombardi F, Rago T, Antonangeli L, Maccherini D, Nanni P, Loviselli A, Balestrieri A, Araneo G: Thyroid volume measurement by ultrasound in children as a tool for the assessment of mild iodine deficiency. J Clin Endocrinol Metab. 1994, 79: 600-603.PubMed
82.
go back to reference Crile G, Schumacher OP: Radioactive iodine treatment of Graves' disease. Results in 32 children under 16 years of age. Am J Dis Child. 1965, 110: 501-504.PubMedCrossRef Crile G, Schumacher OP: Radioactive iodine treatment of Graves' disease. Results in 32 children under 16 years of age. Am J Dis Child. 1965, 110: 501-504.PubMedCrossRef
83.
go back to reference Hayek A, Chapman EM, Crawford JD: Long term results of treatment of thyrotoxicosis in children and adolescents with radioactive iodine (131I) for hyperthyroidism. N Engl J Med. 1970, 283: 949-953.PubMedCrossRef Hayek A, Chapman EM, Crawford JD: Long term results of treatment of thyrotoxicosis in children and adolescents with radioactive iodine (131I) for hyperthyroidism. N Engl J Med. 1970, 283: 949-953.PubMedCrossRef
84.
go back to reference Freitas JE, Swanson DP, Gross MD, Sisson JC: Iodine131-I: optimal therapy for thyroidism in children and adolescents?. J Nucl Med. 1979, 20: 847-850.PubMed Freitas JE, Swanson DP, Gross MD, Sisson JC: Iodine131-I: optimal therapy for thyroidism in children and adolescents?. J Nucl Med. 1979, 20: 847-850.PubMed
85.
go back to reference Starr P, Jaffe HL, Oettinger L: Late results of 131I treatment of hyperthyroidism in 73 children and adoloscents. J Nucl Med. 1964, 5: 81-89.PubMed Starr P, Jaffe HL, Oettinger L: Late results of 131I treatment of hyperthyroidism in 73 children and adoloscents. J Nucl Med. 1964, 5: 81-89.PubMed
86.
go back to reference Starr HJ, Oettinger L: Later results of 131-I treatment of hyperthyroidism in 73 children and adolescence: 1967 follow-up. J Nucl Med. 1969, 10: 586-590.PubMed Starr HJ, Oettinger L: Later results of 131-I treatment of hyperthyroidism in 73 children and adolescence: 1967 follow-up. J Nucl Med. 1969, 10: 586-590.PubMed
87.
go back to reference Kogut MD, Kaplan SA, Collipp PJ, Tiamsic T, Boyle D: Treatment of hyperthyroidism in children: analysis of fourty-five patients. N Engl J Med. 1965, 272: 217-222.PubMedCrossRef Kogut MD, Kaplan SA, Collipp PJ, Tiamsic T, Boyle D: Treatment of hyperthyroidism in children: analysis of fourty-five patients. N Engl J Med. 1965, 272: 217-222.PubMedCrossRef
88.
go back to reference Moll GW, Patel BR: Pediatric Graves' Disease: therapeutic options and experinence with radioiodine at the University of Mississippi Medical center. South Med J. 1997, 90: 1017-PubMedCrossRef Moll GW, Patel BR: Pediatric Graves' Disease: therapeutic options and experinence with radioiodine at the University of Mississippi Medical center. South Med J. 1997, 90: 1017-PubMedCrossRef
89.
go back to reference Safa AM, Schumacher OP, Rodriguez-Antunez A: Long-term follow-up results in children and adolescents treated with radioactive iodine (131I) for hyperthyroidism. N Engl J Med. 1975, 292: 167-171.PubMedCrossRef Safa AM, Schumacher OP, Rodriguez-Antunez A: Long-term follow-up results in children and adolescents treated with radioactive iodine (131I) for hyperthyroidism. N Engl J Med. 1975, 292: 167-171.PubMedCrossRef
90.
go back to reference Rivkees SA, Cornelius EA: Influence of iodine-131 dose on the outcome of hyperthyroidism in children. Pediatrics. 2003, 111: 745-749.PubMedCrossRef Rivkees SA, Cornelius EA: Influence of iodine-131 dose on the outcome of hyperthyroidism in children. Pediatrics. 2003, 111: 745-749.PubMedCrossRef
91.
go back to reference Nebesio TD, Siddiqui AR, Pescovitz OH, Eugster EA: Time course to hypothyroidism after fixed-dose radioablation therapy of Graves' disease in children. J Pediatr. 2002, 141: 99-103.PubMedCrossRef Nebesio TD, Siddiqui AR, Pescovitz OH, Eugster EA: Time course to hypothyroidism after fixed-dose radioablation therapy of Graves' disease in children. J Pediatr. 2002, 141: 99-103.PubMedCrossRef
92.
go back to reference Kalinyak JE, McDougall IR: How should the dose of iodine-131 be determined in the treatment of Graves' hyperthyroidism?. J Clin Endocrinol Metab. 2003, 88: 975-977.PubMedCrossRef Kalinyak JE, McDougall IR: How should the dose of iodine-131 be determined in the treatment of Graves' hyperthyroidism?. J Clin Endocrinol Metab. 2003, 88: 975-977.PubMedCrossRef
93.
go back to reference Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA: A randomized comparison of radioiodine doses in Graves' hyperthyroidism. J Clin Endocrinol Metab. 2003, 88: 978-983.PubMedCrossRef Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA: A randomized comparison of radioiodine doses in Graves' hyperthyroidism. J Clin Endocrinol Metab. 2003, 88: 978-983.PubMedCrossRef
94.
go back to reference Barnes HV, Blizzard RM: Antithyroid drug therapy for toxic diffuse goiter (Graves disease): thirty years experience in children and adolscence. J Pediatr. 1977, 91: 313-320.PubMedCrossRef Barnes HV, Blizzard RM: Antithyroid drug therapy for toxic diffuse goiter (Graves disease): thirty years experience in children and adolscence. J Pediatr. 1977, 91: 313-320.PubMedCrossRef
95.
go back to reference Miccoli P, Vitti P, Rago T, Iacconi P, Bartalena L, Bogazzi F, Fiore E, Valeriano R, Chiovato L, Rocchi R, Pinchera A: Surgical treatment of Graves' disease: subtotal or total thyroidectomy?. Surgery. 1996, 120: 1020-1024. discussion 4–5PubMedCrossRef Miccoli P, Vitti P, Rago T, Iacconi P, Bartalena L, Bogazzi F, Fiore E, Valeriano R, Chiovato L, Rocchi R, Pinchera A: Surgical treatment of Graves' disease: subtotal or total thyroidectomy?. Surgery. 1996, 120: 1020-1024. discussion 4–5PubMedCrossRef
96.
go back to reference Wiersinga WM, Prummel MF: Graves' ophthalmopathy: A rational approach to treatment. Trends Endocrinol Metab. 2002, 13: 280-287.PubMedCrossRef Wiersinga WM, Prummel MF: Graves' ophthalmopathy: A rational approach to treatment. Trends Endocrinol Metab. 2002, 13: 280-287.PubMedCrossRef
97.
go back to reference Sarkar SD, Beierwaltes WH, Gill SP, Cowley BJ: Subsequent fertility and birth histories of children and adolescents treated with 131I for thyroid cancer. J Nucl Med. 1976, 17: 460-464.PubMed Sarkar SD, Beierwaltes WH, Gill SP, Cowley BJ: Subsequent fertility and birth histories of children and adolescents treated with 131I for thyroid cancer. J Nucl Med. 1976, 17: 460-464.PubMed
98.
99.
go back to reference Boice JD: Thyroid disease 60 years after Hiroshima and 20 years after Chernobyl. JAMA. 2006, 295: 1060-1062.PubMedCrossRef Boice JD: Thyroid disease 60 years after Hiroshima and 20 years after Chernobyl. JAMA. 2006, 295: 1060-1062.PubMedCrossRef
100.
go back to reference Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM, Schneider AB, Tucker MA, Boice JD: Thyroid Cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res. 1995, 141: 259-277.PubMedCrossRef Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM, Schneider AB, Tucker MA, Boice JD: Thyroid Cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res. 1995, 141: 259-277.PubMedCrossRef
101.
102.
go back to reference Sigurdson AJ, Ronckers CM, Mertens AC, Stovall M, Smith SA, Liu Y, Berkow RL, Hammond S, Neglia JP, Meadows AT, Sklar CA, Robison LL, Inskip PD: Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case–control study. Lancet. 2005, 365: 2014-2023.PubMedCrossRef Sigurdson AJ, Ronckers CM, Mertens AC, Stovall M, Smith SA, Liu Y, Berkow RL, Hammond S, Neglia JP, Meadows AT, Sklar CA, Robison LL, Inskip PD: Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case–control study. Lancet. 2005, 365: 2014-2023.PubMedCrossRef
103.
go back to reference Flynn RW, Macdonald TM, Jung RT, Morris AD, Leese GP: Mortality and vascular outcomes in patients treated for thyroid dysfunction. J Clin Endocrinol Metab. 2006, 91: 2159-2164.PubMedCrossRef Flynn RW, Macdonald TM, Jung RT, Morris AD, Leese GP: Mortality and vascular outcomes in patients treated for thyroid dysfunction. J Clin Endocrinol Metab. 2006, 91: 2159-2164.PubMedCrossRef
104.
go back to reference Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P: Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med. 1998, 338: 712-718.PubMedCrossRef Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P: Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med. 1998, 338: 712-718.PubMedCrossRef
105.
go back to reference Franklyn JA, Sheppard MC, Maisonneuve P: Thyroid function and mortality in patients treated for hyperthyroidism. JAMA. 2005, 294: 71-80.PubMedCrossRef Franklyn JA, Sheppard MC, Maisonneuve P: Thyroid function and mortality in patients treated for hyperthyroidism. JAMA. 2005, 294: 71-80.PubMedCrossRef
106.
go back to reference Goldman MB, Monson RR, Maloof F: Cancer mortality in women with thyroid disease. Cancer Res. 1990, 50: 2283-2289.PubMed Goldman MB, Monson RR, Maloof F: Cancer mortality in women with thyroid disease. Cancer Res. 1990, 50: 2283-2289.PubMed
107.
go back to reference Holm LE, Hall P, Wiklund K, Lundell G, Berg G, Bjelkengren G, Cederquist E, Ericsson UB, Hallquist A, Larsson LG: Cancer risk after iodine-131 therapy for hyperthyroidism. J Natl Cancer Inst. 1991, 83: 1072-1077.PubMedCrossRef Holm LE, Hall P, Wiklund K, Lundell G, Berg G, Bjelkengren G, Cederquist E, Ericsson UB, Hallquist A, Larsson LG: Cancer risk after iodine-131 therapy for hyperthyroidism. J Natl Cancer Inst. 1991, 83: 1072-1077.PubMedCrossRef
108.
go back to reference Metso S, Jaatinen P, Huhtala H, Auvinen A, Oksala H, Salmi J: Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism. J Clin Endocrinol Metab. 2007, 92: 2190-2196.PubMedCrossRef Metso S, Jaatinen P, Huhtala H, Auvinen A, Oksala H, Salmi J: Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism. J Clin Endocrinol Metab. 2007, 92: 2190-2196.PubMedCrossRef
109.
go back to reference Ron E, Doody MM, Becker DV, Brill AB, Curtis RE, Goldman MB, Harris BS, Hoffman DA, McConahey WM, Maxon HR, Preston-Martin S, Warshauer ME, Wong FL, Boice JD: Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA. 1998, 280: 347-355.PubMedCrossRef Ron E, Doody MM, Becker DV, Brill AB, Curtis RE, Goldman MB, Harris BS, Hoffman DA, McConahey WM, Maxon HR, Preston-Martin S, Warshauer ME, Wong FL, Boice JD: Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA. 1998, 280: 347-355.PubMedCrossRef
110.
go back to reference Read CH, Tansey MJ, Menda Y: A thirty-six year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves' pateints. JCEM. 2004, 89 (9): 4229-4233.PubMed Read CH, Tansey MJ, Menda Y: A thirty-six year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves' pateints. JCEM. 2004, 89 (9): 4229-4233.PubMed
111.
go back to reference Toohey RE, Stabin MG, Watson EE: The AAPM/RSNA physics tutorial for residents: internal radiation dosimetry: principles and applications. Radiographics. 2000, 20: 533-546.PubMedCrossRef Toohey RE, Stabin MG, Watson EE: The AAPM/RSNA physics tutorial for residents: internal radiation dosimetry: principles and applications. Radiographics. 2000, 20: 533-546.PubMedCrossRef
112.
go back to reference Toohey RE, Stabin MG: Comparative analysis of dosimetry parameters for nuclear medicine. ORISE Report 99–1064, 1999. Proceedings of the Sixth International Radiopharmaceutical Dosimetry Symposium. 1996, Gatlinburg, TN, 532-551. Toohey RE, Stabin MG: Comparative analysis of dosimetry parameters for nuclear medicine. ORISE Report 99–1064, 1999. Proceedings of the Sixth International Radiopharmaceutical Dosimetry Symposium. 1996, Gatlinburg, TN, 532-551.
113.
go back to reference Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII – Phase 2. 2006, Washington D.C: National Academies Press Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII – Phase 2. 2006, Washington D.C: National Academies Press
114.
go back to reference Ching T, Warden MJ, Fefferman RA: Thyroid surgery in children and teenagers. Arch Otolaryngol. 1977, 103: 544-546.PubMedCrossRef Ching T, Warden MJ, Fefferman RA: Thyroid surgery in children and teenagers. Arch Otolaryngol. 1977, 103: 544-546.PubMedCrossRef
115.
go back to reference Buckingham BA, Costin G, Roe TF, Weitzman JJ, Kogut MD: Hyperthyroidism in children. A reevaluation of treatment. Am J Dis Child. 1981, 135: 112-117.PubMedCrossRef Buckingham BA, Costin G, Roe TF, Weitzman JJ, Kogut MD: Hyperthyroidism in children. A reevaluation of treatment. Am J Dis Child. 1981, 135: 112-117.PubMedCrossRef
116.
go back to reference Rudberg C, Johansson H, Akerstrom G, Tuvemo T, Karlsson FA: Graves' disease in children and adolescents. Late results of surgical treatment. Eur J Endocrinol/Eur Fed Endocr Soc. 1996, 134: 710-715.CrossRef Rudberg C, Johansson H, Akerstrom G, Tuvemo T, Karlsson FA: Graves' disease in children and adolescents. Late results of surgical treatment. Eur J Endocrinol/Eur Fed Endocr Soc. 1996, 134: 710-715.CrossRef
117.
go back to reference Peters H, Fischer C, Bogner U, Reiners C, Schleusener H: Reduction in thyroid volume after radioiodine therapy of Graves' hyperthyroidism: results of a prospective, randomized, multicentre study. Eur J Clin Invest. 1996, 26: 59-63.PubMedCrossRef Peters H, Fischer C, Bogner U, Reiners C, Schleusener H: Reduction in thyroid volume after radioiodine therapy of Graves' hyperthyroidism: results of a prospective, randomized, multicentre study. Eur J Clin Invest. 1996, 26: 59-63.PubMedCrossRef
118.
go back to reference Sosa JA, Tuggle CT, Wang TS, Thomas DC, Boudourakis L, Rivkees S, Roman SA: Clinical and economic outcomes of thyroid and parathyroid surgery in children. J Clin Endocrinol Metab. 2008, 93: 3058-3065.PubMedCrossRef Sosa JA, Tuggle CT, Wang TS, Thomas DC, Boudourakis L, Rivkees S, Roman SA: Clinical and economic outcomes of thyroid and parathyroid surgery in children. J Clin Endocrinol Metab. 2008, 93: 3058-3065.PubMedCrossRef
119.
go back to reference Breuer CK, Solomon D, Donovan P, Rivkees SA, Udelsman R: Effect of patient Age on surgical outcomes for Graves' disease: a case–control study of 100 consecutive patients at a high volume thyroid surgical center. Int J Pediatr Endocrinol. 2013, 2013: 1-PubMedCentralPubMedCrossRef Breuer CK, Solomon D, Donovan P, Rivkees SA, Udelsman R: Effect of patient Age on surgical outcomes for Graves' disease: a case–control study of 100 consecutive patients at a high volume thyroid surgical center. Int J Pediatr Endocrinol. 2013, 2013: 1-PubMedCentralPubMedCrossRef
120.
go back to reference Lal G, Ituarte P, Kebebew E, Siperstein A, Duh QY, Clark OH: Should total thyroidectomy become the preferred procedure for surgical management of Graves' disease?. Thyroid. 2005, 15: 569-574.PubMedCrossRef Lal G, Ituarte P, Kebebew E, Siperstein A, Duh QY, Clark OH: Should total thyroidectomy become the preferred procedure for surgical management of Graves' disease?. Thyroid. 2005, 15: 569-574.PubMedCrossRef
121.
go back to reference Boger MS, Perrier ND: Advantages and disadvantages of surgical therapy and optimal extent of thyroidectomy for the treatment of hyperthyroidism. Surg Clin N Am. 2004, 84: 849-874.PubMedCrossRef Boger MS, Perrier ND: Advantages and disadvantages of surgical therapy and optimal extent of thyroidectomy for the treatment of hyperthyroidism. Surg Clin N Am. 2004, 84: 849-874.PubMedCrossRef
122.
go back to reference Witte J, Goretzki PE, Dotzenrath C, Simon D, Felis P, Neubauer M, Röher HD: Surgery for Graves' disease: total versus subtotal thyroidectomy-results of a prospective randomized trial. World J Surg. 2000, 24: 1303-1311.PubMedCrossRef Witte J, Goretzki PE, Dotzenrath C, Simon D, Felis P, Neubauer M, Röher HD: Surgery for Graves' disease: total versus subtotal thyroidectomy-results of a prospective randomized trial. World J Surg. 2000, 24: 1303-1311.PubMedCrossRef
123.
go back to reference Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R: The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg. 1998, 228: 320-330.PubMedCentralPubMedCrossRef Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R: The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg. 1998, 228: 320-330.PubMedCentralPubMedCrossRef
124.
go back to reference Breuer C, Tuggle C, Solomon D, Sosa JA: Pediatric thyroid disease: when is surgery necessary, and who should be operating on our children?. J Clin Res Pediatr Endocrinol. 2013, 5 (Suppl 1): 79-85.PubMedCentralPubMed Breuer C, Tuggle C, Solomon D, Sosa JA: Pediatric thyroid disease: when is surgery necessary, and who should be operating on our children?. J Clin Res Pediatr Endocrinol. 2013, 5 (Suppl 1): 79-85.PubMedCentralPubMed
125.
go back to reference Peroni E, Angiolini MR, Vigone MC, Mari G, Chiumello G, Beretta E, Weber G: Surgical management of pediatric Graves' disease: an effective definitive treatment. Pediatr Surg Int. 2012, 28: 609-614.PubMedCrossRef Peroni E, Angiolini MR, Vigone MC, Mari G, Chiumello G, Beretta E, Weber G: Surgical management of pediatric Graves' disease: an effective definitive treatment. Pediatr Surg Int. 2012, 28: 609-614.PubMedCrossRef
126.
go back to reference Read CH, Tansey MJ, Menda Y: A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves' patients. J Clin Endocrinol Metab. 2004, 89: 4229-4233.PubMedCrossRef Read CH, Tansey MJ, Menda Y: A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves' patients. J Clin Endocrinol Metab. 2004, 89: 4229-4233.PubMedCrossRef
127.
go back to reference Wilkins L: The Diaganosis and Treatment of Endocrine Disorders in Children and Adolescence. Hypothyroidism. 1965, Charles Thomas, Springfield, 141-150. Wilkins L: The Diaganosis and Treatment of Endocrine Disorders in Children and Adolescence. Hypothyroidism. 1965, Charles Thomas, Springfield, 141-150.
128.
go back to reference Davies T, Roti E, Braverman LE, De Groot LJ: Thyroid conterversy–stimulating antibodies. J Clin Endocrinol Metab. 1998, 83: 3777-3785.PubMedCrossRef Davies T, Roti E, Braverman LE, De Groot LJ: Thyroid conterversy–stimulating antibodies. J Clin Endocrinol Metab. 1998, 83: 3777-3785.PubMedCrossRef
129.
go back to reference Wilson R, McKilop JH, Henderson N, Pearson DW, Thomson JA: The ability of the serum throtrophin receptr antibody (TRAb) index and HLA status to predict long-term remission of thyrotoxicosis following medical therapy for Graves' disease. Clin Endocrinol (Oxf). 1986, 25 (2): 151-156.CrossRef Wilson R, McKilop JH, Henderson N, Pearson DW, Thomson JA: The ability of the serum throtrophin receptr antibody (TRAb) index and HLA status to predict long-term remission of thyrotoxicosis following medical therapy for Graves' disease. Clin Endocrinol (Oxf). 1986, 25 (2): 151-156.CrossRef
Metadata
Title
Pediatric Graves’ disease: management in the post-propylthiouracil Era
Author
Scott A Rivkees
Publication date
01-12-2014
Publisher
BioMed Central
Published in
International Journal of Pediatric Endocrinology / Issue 1/2014
Electronic ISSN: 1687-9856
DOI
https://doi.org/10.1186/1687-9856-2014-10

Other articles of this Issue 1/2014

International Journal of Pediatric Endocrinology 1/2014 Go to the issue